<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860833</url>
  </required_header>
  <id_info>
    <org_study_id>LGOG1</org_study_id>
    <nct_id>NCT01860833</nct_id>
  </id_info>
  <brief_title>NSAID Treatment in Knee Osteoarthritis</brief_title>
  <acronym>NSKO</acronym>
  <official_title>EFFECTS OF NSAIDs ON CLINICAL OUTCOMES, SYNOVIAL FLUID CYTOKINE CONCENTRATION AND SIGNAL TRANSDUCTION PATHWAYS IN KNEE OSTEOARTHRITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cantanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cantanzaro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central mechanisms may play a role in pain perception during osteoarthritis (OA).Local
      inflammation (which involves production of pro-inflammatory cytokines such as interleukin
      (IL) 4 TNF-alpha, IL-6 and IL-8) is considered to be a major source of pain.

      Certain therapies that specifically interfere with the expression or actions of
      pro-inflammatory cytokines have been explored. NSAIDs have analgesic, antipyretic and
      anti-inflammatory properties and are extensively prescribed for several musculoskeletal
      disorders. Indeed, the Osteoarthritis Research Society International (OARSI) recently
      recommended the use of NSAIDs for management of knee and hip OA in symptomatic patients.
      These drugs have been shown to influence cytokine metabolism in the synovial fluid of OA
      patients with satisfactory relief of painful osteoarthritic joints.

      The aim of the current study was to explore whether NSAID treatment inhibits TNF-alpha, IL-6,
      IL-8, and VEGF secretion in the synovial fluid of osteoarthritic joints. In particular,
      diclofenac, ibuprofen and celecoxib were studied. Under the hypothesis that relationships
      between proinflammatory cytokines and the clinical status of OA patients are possible, we
      also evaluated the association between the concentration of these molecules in the
      osteoarthritic knee synovial fluid and the pain and functional status of patients with OA.
      The effects of NSAIDS on signal transduction pathways in the synovial membrane were also
      investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      not desired
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Western Ontario and McMaster universities (WOMAC) osteoarthritis index score</measure>
    <time_frame>0-14 days</time_frame>
    <description>Womac was used to 77 measure the disease-specific health status of patients before and after the pharmacological treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Naranjo probability scale</measure>
    <time_frame>14 days</time_frame>
    <description>The Naranjo probability scale was used to evaluate the development of adverse drug reaction during this study</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>diclofenac 75 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diclofenac 75 mg once day slow release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diclofenac 150 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diclofenac 75 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen 1200 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ibuprofen 600 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen 1800 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ibuprofen 600 mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>celecoxib 200 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>celecoxib 200 mg once day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>celecoxib 400 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>celecoxib 200 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>time of treatment 14 days</description>
    <arm_group_label>ibuprofen 1200 mg/day</arm_group_label>
    <arm_group_label>ibuprofen 1800 mg/day</arm_group_label>
    <other_name>Brufen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>time of treatment 14 days</description>
    <arm_group_label>celecoxib 200 mg/day</arm_group_label>
    <arm_group_label>celecoxib 400 mg/day</arm_group_label>
    <other_name>celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>time of treatment 14 days</description>
    <arm_group_label>diclofenac 75 mg/day</arm_group_label>
    <arm_group_label>diclofenac 150 mg/day</arm_group_label>
    <other_name>voltaren</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients eligible for the study were:

          -  older than 50 years and

          -  had primary knee OA diagnosed according to the clinical and radiological criteria of
             the American Rheumatism Association.

        Further inclusion criteria were:

          -  clinical signs of joint inflammation (warmth, swelling or effusion) and

          -  a disease severity grade 2 or 3 according to the Kellgren-Lawrence classification

        Exclusion Criteria:

          -  allergy to NSAIDs,

          -  progressive serious medical conditions (such as cancer, AIDS or end-stage renal
             disease),

          -  history of gastrointestinal ulcer or bleeding,

          -  a hemoglobin concentration lower than 11.5 g/dL,

          -  renal diseases (serum creatinine concentration more than 1.2 times the upper limit of
             the normal range according to the central laboratory definition reference values), or

          -  liver dysfunction (serum alanine or aspartate transaminase concentrations more than
             1.5 times the upper limit of normal range according to the central laboratory
             definition reference values).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Gallelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Catanzaro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Orthopedic and Trauma Surgery</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>May 22, 2013</last_update_submitted>
  <last_update_submitted_qc>May 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cantanzaro</investigator_affiliation>
    <investigator_full_name>Luca Gallelli</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

